PATIENTS WITH SOME TYPES of breast cancer will have a new clinical trial option at Fox Chase Cancer Center. Medical oncologists Lori Goldstein, MD, and Elias Obeid, MD, MPH, are opening a phase II immunotherapy clinical trial for newly diagnosed, locally recurrent, or metastatic HER2-overexpressing breast cancer.
The investigators are seeking to learn how the programmed cell death ligand 1 inhibitor atezolizumab (Tecentriq) works when used in combination with the standard-of-care regimen of paclitaxel, pertuzumab (Perjeta), and trastuzumab (Herceptin). This clinical trial will study both the safety and efficacy of the drug combination in treating this type of breast cancer. ■
